Crossmark

A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study

Crossref DOI link: https://doi.org/10.1038/leu.2015.313

Published Online: 2015-12-07

Published Print: 2016-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

,

Rawstron, A C

Fazi, C

Agathangelidis, A

Villamor, N

Letestu, R

Nomdedeu, J

Palacio, C

Stehlikova, O

Kreuzer, K-A

Liptrot, S

O'Brien, D

de Tute, R M

Marinov, I

Hauwel, M

Spacek, M

Dobber, J

Kater, A P

Gambell, P

Soosapilla, A

Lozanski, G

Brachtl, G

Lin, K

Boysen, J

Hanson, C

Jorgensen, J L

Stetler-Stevenson, M

Yuan, C

Broome, H E

Rassenti, L

Craig, F

Delgado, J

Moreno, C

Bosch, F

Egle, A

Doubek, M

Pospisilova, S

Mulligan, S

Westerman, D

Sanders, C M

Emerson, R

Robins, H S

Kirsch, I

Shanafelt, T

Pettitt, A

Kipps, T J

Wierda, W G

Cymbalista, F

Hallek, M

Hillmen, P

Montserrat, E

Ghia, P
License Information

Text and Data Mining valid from 2015-12-07
More Information

Article History

Received: 8 May 2015

Revised: 14 August 2015

Accepted: 14 September 2015

First Online: 7 December 2015

Competing interests

: The type of relationship with the organizations are: ACR: Celgene, Honoraria; BD Biosciences, royalty payments (Intrasure reagent) and study reagents; Abbvie, Honoraria; Gilead, Consultancy and Honoraria; Biogen Idec, Consultancy; Roche, Honoraria; and GSK, Honoraria. PG: AbbVie, Honoraria; Adaptive Biotechnologies, Consultancy; Celgene, Consultancy; Gilead, Consultancy, Honoraria and research funds; GSK, research funds; Janssen, Consultancy and Honoraria; Pharmacyclics, Consultancy; and Roche, Research funds. All other co-authors report no conflicts of interest.

Document is current

Any future updates will be listed below